Boulter E A, Thornton B, Bauer D J, Bye A
Br Med J. 1980 Mar 8;280(6215):681-3. doi: 10.1136/bmj.280.6215.681.
The efficacy of the new nucleoside analogue acyclovir against B virus (Herpesvirus simiae) was investigated in rabbits and Vero cells infected with 2-136 and 0.3-1.0 TCD50 of the virus respectively. In the Vero cells 1 mg of acyclovir/1 reduced the yield of virus by 90%, which was slightly less than the effect on herpes simplex virus. Results in the rabbits varied with the interval between doses, duration of treatment, and delay before starting treatment. Acyclovir controlled an otherwise lethal infection when given not less than eight-hourly for 14 days. Withdrawing treatment after 9-10 days resulted in late-onset fatal disease in some rabbits. Treatment begun within 24 hours after infection gave complete protection, and rabbits first treated up to five days after infection showed a significant reduction in mortality (p less than 0.001). The plasma half life of acyclovir is twice as long in man as in rabbits and progression of the disease is much slower. Hence acyclovir may be useful for post-exposure prophylaxis against B virus infection in man and possibly also for treatment of the disease.
在分别感染了2 - 136和0.3 - 1.0半数组织培养感染剂量（TCD50）该病毒的兔子和非洲绿猴肾（Vero）细胞中，研究了新型核苷类似物阿昔洛韦对B病毒（猴疱疹病毒）的疗效。在Vero细胞中，1毫克/升的阿昔洛韦使病毒产量降低了90%，这略低于对单纯疱疹病毒的作用效果。兔子实验的结果因给药间隔、治疗持续时间以及开始治疗前的延迟时间而异。当每8小时给药一次，持续14天时，阿昔洛韦控制住了原本会致命的感染。在9 - 10天后停止治疗，导致一些兔子出现迟发性致命疾病。在感染后24小时内开始治疗可提供完全保护，而在感染后长达五天首次接受治疗的兔子死亡率显著降低（p小于0.001）。阿昔洛韦在人体内的血浆半衰期是兔子的两倍，且疾病进展要慢得多。因此，阿昔洛韦可能有助于人类暴露后预防B病毒感染，也可能用于治疗该疾病。
